Edgewise Therapeutics, Inc. (EWTX) stock
EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$41.37−0.67 (-1.59%)
Close on Nov 18, 2026Market cap $4.49BP/E –Yield –
Edgewise Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Edgewise Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$218.90M. For fiscal 2025 it was -$191.41M. The highest annual figure on record is -$17.19M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$191.41M | – |
| FY2024 | Dec 31, 2024 | -$158.83M | – |
| FY2023 | Dec 31, 2023 | -$114.36M | – |
| FY2022 | Dec 31, 2022 | -$71.66M | – |
| FY2021 | Dec 31, 2021 | -$43.22M | – |
| FY2020 | Dec 31, 2020 | -$17.19M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$61.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$54.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$55.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$42.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$45.96M | – |
| Q4 FY2024 | Dec 31, 2024 | -$45.54M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.43M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$29.45M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.70M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.49M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.46M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.96M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.25M | – |
See a number that looks wrong?